1. Home
  2. SNY vs PHLT Comparison

SNY vs PHLT Comparison

Compare SNY & PHLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNY
  • PHLT
  • Stock Information
  • Founded
  • SNY 1994
  • PHLT 1976
  • Country
  • SNY France
  • PHLT United States
  • Employees
  • SNY N/A
  • PHLT N/A
  • Industry
  • SNY Biotechnology: Pharmaceutical Preparations
  • PHLT Other Consumer Services
  • Sector
  • SNY Health Care
  • PHLT Consumer Discretionary
  • Exchange
  • SNY Nasdaq
  • PHLT Nasdaq
  • Market Cap
  • SNY 123.6B
  • PHLT N/A
  • IPO Year
  • SNY N/A
  • PHLT N/A
  • Fundamental
  • Price
  • SNY $53.63
  • PHLT $2.41
  • Analyst Decision
  • SNY Buy
  • PHLT
  • Analyst Count
  • SNY 2
  • PHLT 0
  • Target Price
  • SNY $62.50
  • PHLT N/A
  • AVG Volume (30 Days)
  • SNY 3.6M
  • PHLT 157.2K
  • Earning Date
  • SNY 04-24-2025
  • PHLT 05-06-2025
  • Dividend Yield
  • SNY 3.08%
  • PHLT N/A
  • EPS Growth
  • SNY 39.56
  • PHLT N/A
  • EPS
  • SNY 5.45
  • PHLT N/A
  • Revenue
  • SNY $48,817,552,946.00
  • PHLT $122,981,000.00
  • Revenue This Year
  • SNY $5.35
  • PHLT $10.03
  • Revenue Next Year
  • SNY $6.69
  • PHLT $11.87
  • P/E Ratio
  • SNY $9.60
  • PHLT N/A
  • Revenue Growth
  • SNY N/A
  • PHLT 8.12
  • 52 Week Low
  • SNY $45.80
  • PHLT $2.26
  • 52 Week High
  • SNY $60.12
  • PHLT $4.35
  • Technical
  • Relative Strength Index (RSI)
  • SNY 50.20
  • PHLT N/A
  • Support Level
  • SNY $50.46
  • PHLT N/A
  • Resistance Level
  • SNY $51.64
  • PHLT N/A
  • Average True Range (ATR)
  • SNY 1.60
  • PHLT 0.00
  • MACD
  • SNY 0.15
  • PHLT 0.00
  • Stochastic Oscillator
  • SNY 65.92
  • PHLT 0.00

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Share on Social Networks: